Ginkgo bioworks announces collaboration with merck to improve active pharmaceutical ingredient manufacturing

Ginkgo to engineer key biocatalytic enzymes for potential use in merck's drug manufacturing processes boston , oct. 11, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced a collaboration with merck, known as msd outside the united states and canada, to engineer up to four enzymes for use as biocatalysts in merck's active pharmaceutical ingredient (api) manufacturing efforts. through this collaboration, ginkgo will leverage its extensive experience in cell engineering and enzyme design, as well as its capabilities in automated high throughput screening, manufacturing process development/optimization, bioinformatics and analytics to deliver optimal strains for expression of targeted biocatalysts.
DNA Ratings Summary
DNA Quant Ranking